Form 4: BioLife Solutions CTO Sells Shares for Tax Obligations

BioLife Solutions' Chief Technology Officer, Sean Werner, sold 110 shares of common stock for $26.74 per share to cover tax withholding obligations under a pre-arranged 10b5-1 plan.

Summary

• Sean Werner, Chief Technology Officer of BIOLIFE SOLUTIONS INC (BLFS), reported a sale of common stock.
• The transaction involved the disposition of 110 shares of common stock on November 25, 2025.
• The shares were sold at a price of $26.74 per share.
• Following this transaction, Sean Werner beneficially owns 25,927 shares of common stock directly.
• The sale was executed pursuant to a Rule 10b5-1(c) trading plan, which was adopted on February 24, 2022.
• The primary purpose of the sale was to satisfy tax withholding obligations associated with the vesting of restricted stock.

Sentiment

Score: 5

Explanation: The transaction is a routine, pre-planned sale for tax purposes, which is generally neutral. It's not a discretionary sale indicating a lack of confidence, nor is it an acquisition.

Positives

• The sale was conducted under a Rule 10b5-1(c) trading plan, indicating a pre-planned transaction rather than a discretionary sale based on new information, which reduces concerns about insider trading.
• The stated reason for the sale is to satisfy tax withholding obligations related to restricted stock vesting, a common and routine event for executives, rather than a signal of lack of confidence in the company.

Negatives

• Any insider selling, even for tax purposes, can sometimes be perceived negatively by the market, though the amount here is relatively small.

Risks

• No specific risks are mentioned in this Form 4 filing beyond the general market perception of insider selling.

Future Outlook

NA

Management Comments

• The sale reported herein was made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Industry Context

NA

Stakeholder Impact

• Minimal direct impact on shareholders as it's a small, pre-planned, tax-related sale by an insider.
• Employees might view this as a standard part of executive compensation and tax planning.

Key Dates

Recommendation

The reported transaction is a routine, pre-planned sale by a Chief Technology Officer to cover tax obligations related to restricted stock vesting. It does not signal a change in the company's fundamentals or management's confidence, nor does it suggest any new positive or negative developments. Therefore, a 'hold' recommendation is appropriate as this specific filing provides no new information to alter an existing investment thesis.

Keywords

BioLife Solutions, BLFS, Sean Werner, CTO, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Tax Withholding, Restricted Stock